Paediatric Onco-Haematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children's Hospital, Turin, Italy.
Department of Public Health and Paediatric Sciences, University of Torino, Turin, Italy.
Br J Haematol. 2020 Jul;190(1):93-104. doi: 10.1111/bjh.16508. Epub 2020 Feb 21.
Diamond-Blackfan anaemia (DBA) is a rare and heterogeneous disease characterised by hypoplastic anaemia, congenital anomalies and a predisposition for malignancies. The aim of this paper is to report the findings from the Italian DBA Registry, and to discuss the Registry's future challenges in tackling this disease. Our 20-year long work allowed the connection of 50 Italian Association of Paediatric Haematology and Oncology (AIEOP) centres and the recruitment of 283 cases. Almost all patients have been characterised at a molecular level (96%, 271/283), finding a causative mutation in 68% (184/271). We confirm the importance of determination of erythrocyte adenosine deaminase activity (eADA) and of ribosomal RNA assay in the diagnostic pipeline and characterisation of a remission state. Patients with mutations in large ribosomal subunit protein (RPL) genes had a significant correlation with the incidence of malformations, higher eADA levels and more severe outcomes, compared to patients with mutations in small ribosomal subunit protein (RPS) genes. Furthermore, as a consequence of our findings, particularly the incidence of malignancies and the high percentage of patients aged >18 years, we stress the importance of collaboration with adult clinicians to guarantee regular multi-specialist follow-up. In conclusion, this study highlights the importance of national registries to increase our understanding and improve management of this complex disease.
Diamond-Blackfan 贫血(DBA)是一种罕见且异质性的疾病,其特征为再生障碍性贫血、先天性异常和恶性肿瘤易感性。本文旨在报告意大利 DBA 注册研究的结果,并讨论该注册研究在应对这种疾病方面未来面临的挑战。我们 20 年的工作使我们得以联系意大利儿科血液学和肿瘤学会(AIEOP)的 50 个中心,并招募了 283 例病例。几乎所有患者都进行了分子水平的特征分析(96%,271/283),发现 68%(184/271)的患者存在致病突变。我们证实了在诊断流程中确定红细胞腺苷脱氨酶活性(eADA)和核糖体 RNA 分析的重要性,以及在缓解状态下的特征分析。与小核糖体亚基蛋白(RPS)基因突变患者相比,大核糖体亚基蛋白(RPL)基因突变患者与畸形发生率、更高的 eADA 水平和更严重的结局之间存在显著相关性。此外,鉴于我们的发现,特别是恶性肿瘤的发病率和>18 岁患者的高比例,我们强调与成人临床医生合作的重要性,以保证定期的多学科随访。总之,这项研究强调了国家注册研究的重要性,以提高我们对这种复杂疾病的认识并改善其管理。